Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that an independent data safety monitoring board (DSMB) found no safety issues and recommended continuation of the company's Phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). The DSMB completed an interim evaluation of safety data after the two-month follow-up visits for the first 20 hematopoietic stem cell transplant (HCT) recipients enrolled in the study.

Because most HCT recipients are expected to face a natural viral challenge as pre-existing CMV infection reactivates under immunosuppression, the primary efficacy endpoint in the double-blind, placebo-controlled Phase 2 trial is the occurrence rate of clinically significant CMV levels in HCT patients receiving vaccine compared with patients receiving placebo. Other important endpoints include immune responses against the specific CMV features targeted by the vaccine. The trial also is comparing safety of the vaccine against placebo in up to 80 matched, related HCT donors and recipients, and up to 80 additional HCT recipients. The DSMB evaluated safety data only in the interim analysis.

About CMV

CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries. While a healthy immune system typically protects an infected person against CMV disease, it rarely succeeds in completely eliminating the infection, and those whose immune systems are not fully functional are at high risk of CMV proliferation, potentially leading to severe illness or death. These include transplant patients who take immunosuppressive drugs, and fetuses and newborns of mothers who first be
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 On the afternoon of August ... of CPI International, Inc. (CPI), plans to file its ... 2015 with the Securities and Exchange Commission and to ... quarter.  At 11 a.m. (EDT) on Wednesday, August 12, ... conjunction with this release that will be Web cast ...
(Date:7/28/2015)... 2015 A German Diabetes Center clinical study ... probiotic enriches human gut microbiota and modifies gut ... study involved daily administration of Nutraceutix,s L. reuteri ... patented BIO- tract ® delivery technology that ... their way to the intestinal tract. The ...
(Date:7/28/2015)... July 28, 2015 The Physician-Patient Alliance for ... fundraising campaign, " Surviving Your Hospital Stay ." ... they deserve! None of these patients went home from ... Executive Director, PPAHS) referring to the patient stories ... National Coalition to Promote Continuous Monitoring of Patients on ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2
... , ... (OTC Bulletin Board: HFGB), a leading developer and producer,of plant ... food production in Xi,an, China, today reported that in its,third ... Revenues for the quarter ended Sept. ...
... , NORTH HOLLYWOOD, Calif., Nov. ... a leading national hospitalist physician group practice company, announced today that ... ACP Hospitalist as one of the 2009 Top Ten Hospitalists ... of the magazine. , Dr. Vaidyan has been a practicing physician ...
Cached Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 3
(Date:7/28/2015)... , ... July 28, 2015 , ... ... products, announces Shelled Out, a new household invention that makes shelling eggs an ... billion by 2020,” says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:7/28/2015)... ... ... By 2016, the number of smartphones worldwide will surpass 2 billion. This means that ... increasing customer loyalty. However, capitalizing on this is not always obvious. Companies that do ... competitors. , The Open Mobile Summit 2015 is an influential gathering of mobile visionaries ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont leaders today joined public ... learn more about the impact of U.S. collaborations with local partners under the ... agricultural development as an engine of broad-based economic growth in the region. ...
(Date:7/28/2015)... ... 2015 , ... opaJUMP! and O-PA! Performance Academy in ... associated with its training methods. This company is also the first to promise ... in early 2015, training yielded an average 80% improvement in functional health status ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
Breaking Medicine News(10 mins):Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3
... Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, ... Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), has extended ... purchase of all outstanding Ordinary Shares of Taro Pharmaceutical ... at 5:00 p.m., New York City time, on Friday, ...
... finds that for some groups, survival odds after angioplasty ... News) -- A major international study pinpoints which people ... having bypass surgery than artery-opening angioplasty. , "Bypass surgery ... said Dr. Mark Hlatky, professor of health research and ...
... New Definition of ,Bedside Manner,WASHINGTON and RED BANK, N.J., ... (NWHRC) just released the latest issue of its ... Care Reform." The report coincides with the start ... support and awareness of the need for comprehensive health ...
... 20 -- Today, the Migraine Research Foundation (MRF) announced ... pediatric and adolescent migraine called FOR OUR CHILDREN. ... to further the understanding of migraine and its causes ... and adolescents. , Migraine is very common ...
... Message That Pulmonary Fibrosis Can Strike Anyone, Anywhere; Urges Americans ... March 20 Pulmonary Fibrosis (PF) claims a life every ... each year as to breast cancer; yet most Americans have ... someone they love. The Coalition for Pulmonary Fibrosis (CPF) ...
... is that hepatocyte necrosis is the main feature of ... role for hepatocyte apoptosis in this pathogenesis. It is ... in the pathogenesis of fulminant hepatic failure. To ascertain ... the protective effect of a cathepsin B inhibitor (CA-074Me) ...
Cached Medicine News:Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:National Women's Health Report Addresses Issues of Uninsured Plus New Paradigms of Care 2Health News:New initiative to support pediatric migraine research is announced 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 3
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
... Made Toric soft contact lenses let you enjoy ... soft toric lens in a lens custom made ... comfort is made possible by PC Technology™, which ... (PC), a substance found naturally in human cell ...
Soft contacts for even the most challenging astigmatic prescriptions. Custom-manufactured according to patient specific prescription, gives the most precise fit possible....
... Great vision and disposable lens convenience ... have astigmatism and want crisp, clear vision ... consider Vertex Toric. Vertex Toric lenses are ... process that produces a perfect edge on ...
Medicine Products: